William Blair analyst Tim Lugo initiates coverage on VistaGen Therapeutics (NASDAQ: VTGN) with a Outperform rating with a $7 fair ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE